A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Vertex Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Cystic Fibrosis

Treatments: Drug: IVA; Drug: Placebo (matched to ELX/TEZ/IVA); Drug: ELX/TEZ/IVA; Drug: Placebo (matched to VX-121/TEZ/D-IVA); Drug: VX-121/TEZ/D-IVA; Drug: Placebo (matched to IVA)

Study type: Interventional

Funder types: Industry

Identifiers

NCT05033080

2021-000712-31 (EudraCT Number)

VX20-121-102

Details and patient eligibility

About

The purpose of this study evaluates the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who were heterozygous for F508del and a minimal function mutation (F/MF participants).

Enrollment: 435 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Heterozygous for F508del and a minimal function mutation (F/MF genotype)
• Forced expiratory volume in 1 second (FEV1) value >=40% and <=90% of predicted mean for age, sex, and height for participants currently receiving ELX/TEZ/IVA therapy; FEV1 >=40% and <=80% for participants not currently receiving ELX/TEZ/IVA

Key Exclusion Criteria:

• History of solid organ or hematological transplantation
• Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
• Lung infection with organisms associated with a more rapid decline in pulmonary status
• Pregnant or breast-feeding females

Other protocol defined Inclusion/Exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

435 participants in 2 patient groups

ELX/TEZ/IVA

Active Comparator group

Description:

Following elexacftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) run-in period of 4 weeks, participants received ELX 200 milligram (mg) once daily (qd) /TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 52 weeks.

Treatment:

Drug: Placebo (matched to VX-121/TEZ/D-IVA)

Drug: ELX/TEZ/IVA

Drug: IVA

VX-121/TEZ/D-IVA

Experimental group

Description:

Following ELX/TEZ/IVA run-in period of 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/D-IVA 250 mg qd in the treatment period for 52 weeks.

Treatment:

Drug: Placebo (matched to IVA)

Drug: VX-121/TEZ/D-IVA

Drug: Placebo (matched to ELX/TEZ/IVA)